No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

Maraviroc is a C‐C chemokine receptor type‐5 antagonist approved for the treatment of HIV‐1. Previous studies show that cytochrome P450 3A5 (CYP3A5) plays a role in maraviroc metabolism. CYP3A5 is subject to a genetic polymorphism. The presence of 2 functional alleles (CYP3A5*1/*1) confers the exten...

Descripción completa

Detalles Bibliográficos
Autores principales: Vourvahis, Manoli, McFadyen, Lynn, Nepal, Sunil, Valluri, Srinivas Rao, Fang, Annie, Fate, Gwendolyn D., Wood, Linda S., Marshall, Jean‐Claude, Chan, Phylinda L. S., Nedderman, Angus, Haynes, Julian, Savage, Mark E., Clark, Andrew, Smith, Kimberly Y., Heera, Jayvant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pharmacogenomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586010/
https://www.ncbi.nlm.nih.gov/pubmed/30192390
http://dx.doi.org/10.1002/jcph.1306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586010/
https://www.ncbi.nlm.nih.gov/pubmed/30192390
http://dx.doi.org/10.1002/jcph.1306

Ejemplares similares